Business Wire

American Airlines Pilots First to Use CEFA Aviation Flight Replay App in the U.S.

7.12.2021 13:16:00 EET | Business Wire | Press release

Share

American Airlines, the world’s largest airline, is the first carrier in the U.S. to adopt CEFA AMS, an Electronic Flight Bag (EFB) application allowing pilots to virtually review flight data on their tablet after landing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005055/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing. (Photo: Business Wire)

CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing.

Captain Neil Raaz, Operations Safety Director at American Airlines, says that CEFA AMS is the next step in American’s data-driven approach to relentlessly advance safety. “By choosing CEFA AMS, we are now able to advance the Safety-II approach in a practical way in our operations. This progressive new debriefing capability will help promote a culture of continuous self-improvement and reinforce American’s safety-first mentality into each and every flight.”

“We are delighted to partner with American Airlines, who sets the standard when it comes to flight safety,” says Dominique Mineo, CEO of CEFA Aviation , a France-based software company specialized in flight safety and pilot training. “Being able to deploy our innovation in the U.S. was one of our main ambitions. Today we have the opportunity to work with an airline committed to the highest safety standards and, beyond the conventional safety approach, aiming for Safety-II implementation.” Mineo added.

The implementation of CEFA Aviation’s EFB flight replay capability is a milestone for American. It demonstrates its will for innovation as well as a strong desire to lead the shift in pilot empowerment through increased access to and awareness of operational flight data.

This new partnership between CEFA and American Airlines will create an entirely new and revolutionary approach to proactive safety in airline operations and clearly demonstrates both organization’s commitment to being industry leaders in aviation safety.

About CEFA Aviation

CEFA Aviation, a privately held French company, enhances pilot training and flight safety, developing world-leading 3D animation software and services for the past 20 years. The innovative solutions developed by its experts recreate flights with high details and accuracy based on data from aircraft flight recorders.

More than 100 major and regional airlines, cargo operators, and investigative authorities on five continents are using the company’s core software, CEFA FAS (Flight Animation System), for pilot training and safety analysis.

Translating flight data into precise visualization requires an in-depth understanding of the complexity of aircraft systems and software engineering. CEFA Aviation has been a pioneer in easy-to-use flight data animation since Dominique Mineo founded the company in 2000. Its long-lasting success is attributable to a passion for aviation and innovation, listening to its clients, and delivering gold-standard support. CEFA Aviation is headquartered in the Alsace region of France.

At the Dubai Airshow 2017, CEFA Aviation unveiled a new breakthrough visualization tool to enhance further and personalize pilot training: CEFA AMS. Additional information can be found at www.cefa-aviation.com

Join us on social media and never miss a press release on Twitter @CEFAAviation and LinkedIn at www.linkedin.com/company/cefa-aviation

About American Airlines Group

American’s purpose is to care for people on life’s journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company’s stock is included in the S&P 500. Learn more about what’s happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CEFA Aviation
Paulina Calderon
communication@cefa-aviation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye